Invested with a long tradition in this field of expertise, the development of the various intraocular lenses (IOLs) reflects Johnson and Johnson’s (J&J) support in the progress of optics in terms of understanding the qualitative vision, its evaluation, and the integration of these factors in the development of their implants. Thus, AMO has become a pioneer in aspherical implants with the proposal of the first monofocal implant with negative spherical aberration validated by the FDA for the optimized mesopic vision it provides. A pioneer in the field of multifocality, where it reigned supreme for more than 10 years with the Rezoom® refractive implant, J&J (Previously AMO) also accompanied the return of diffractive concepts with the arrival of the bifocal TECNIS®, which will be successively developed with variable additions (+4, +3.25, and + 2.75 D), in order to be as personalized as possible to the needs of each patient. But it is undoubtedly the development of the Symfony®, with an extended focal zone, inaugurating the field of the so-called extended depth of field implants, which has made the great success of J&J’s surgical department. This implant would be positioned as a good compromise between a monofocal (correcting only distance vision but with 100% of the light transmitted to the retina) and a multifocal with two distinct focal points (ensuring good near and far vision but at the cost of sometimes reported photic phenomena). Lastly, we must not forget the common denominator of all these implants, which is the hydrophobic biomaterial, glistening free, and the C-loop one-piece design with a preventive square edge of the PCO. We propose here to describe this TECNIS® platform, to discuss the optical specificities of the different available concepts, and to review the reported clinical results in order to establish a state of the art between theoretical advantages and clinical reality.